Global Pharmaceuticals is the generics division of Impax Laboratories, Inc. Impax Laboratories is a technology-based specialty pharmaceutical company and a leader in the development, manufacturing, and marketing of prescription pharmaceutical products utilizing our formulation expertise and unique drug delivery technologies.
We are focused on targeting high-margin, first-to-file, or first-to-market product opportunities. We explore a broad range of therapeutic areas that have technically challenging drug delivery mechanisms or other niches that may result in lessened competition. We are also developing specialty generic products we believe present one or more competitive barriers to entry.
We currently manufacture and market 93 generic pharmaceutical products, which represent dosage variations of 29 different pharmaceutical compounds through our Global Pharmaceuticals Division; another 16 of our generic pharmaceutical products representing dosage variations of 4 different pharmaceutical compounds are marketed by our alliance agreement partners.
Our current generic pipeline has never been more valuable than it is today with more first-to-file and first-to-market opportunities either pending or under development than ever before. We currently have 36 pending ANDAs with at least 7 ANDAs having first-to-file or first-to-market potential. We are also working on an additional 62 products under development, with many having the potential to be first-to-file or first-to-market opportunities. For 2011, our internal/external goal is to file at least 12 new applications with at least 3 of these being first-to-file or first-to-market opportunities.
Along with our parent company, Impax Laboratories, Global Pharmaceuticals continues to invest in state-of-theart equipment, people, and facilities, in order to provide the highest level of research and development, manufacturing, and customer service. Our quality assurance team works closely with our suppliers to ensure purity, consistency, and quality of products, and we strive to bring value to our customers with innovative products in key therapeutic areas.
Global Pharmaceuticals has a dedicated team of experienced professionals handling customer orders and inquiries that work to not only meet the expectations of our customers, but consistently deliver beyond expectations. Every member of our team is committed to the success and profitability of our customers. We have set the highest standards for our products, services, and people, and we are proud of the organization we are building. PT
For more information, please visit: www.globalphar.com.
Fenofibrate Tablets, 54 mg, 160 mg (90-count), and 160 mg (500-count)
Doxycycline Capsules USP, 150 mg (60-count)
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs